Mark C. Kelley

9.1k total citations
26 papers, 1.3k citations indexed

About

Mark C. Kelley is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Mark C. Kelley has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Mark C. Kelley's work include Immunotherapy and Immune Responses (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Cells and Metastasis (4 papers). Mark C. Kelley is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Cells and Metastasis (4 papers). Mark C. Kelley collaborates with scholars based in United States, Australia and Italy. Mark C. Kelley's co-authors include Donald L. Morton, Guy Gammon, Mark B. Faries, John F. Thompson, Robert M. Elashoff, Michael P. Hocking, Charles A. Sninsky, Richard M. Caprioli, Deming Mi and Robert L. Low and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Surgery.

In The Last Decade

Mark C. Kelley

25 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark C. Kelley

Since Specialization

Citations

This map shows the geographic impact of Mark C. Kelley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Kelley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Kelley more than expected).

Fields of papers citing papers by Mark C. Kelley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Kelley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Kelley. The network helps show where Mark C. Kelley may publish in the future.

Co-authorship network of co-authors of Mark C. Kelley

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Kelley. A scholar is included among the top collaborators of Mark C. Kelley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Kelley. Mark C. Kelley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation 2017 ·Cancer Discovery ·Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley H. Lomeli, Jin Qian, Clarissa C. Yu, Robert Damoiseaux, Mark C. Kelley, (unknown), Philip O. Scumpia, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Willy Hugo, Roger S. Lo	109
2	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases 2017 ·Annals of Surgical Oncology ·Mark B. Faries, Nicola Mozzillo, Mohammed Kashani–Sabet, John F. Thompson, Mark C. Kelley, Ronald C. DeConti, Jeffrey E. Lee, James F. Huth, Jeffrey D. Wagner, Angus Dalgleish, (unknown), Christopher Nardo, Stacey L. Stern, Robert M. Elashoff, Guy Gammon, Donald L. Morton	85
3	Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? 2016 ·Critical Reviews™ in Oncogenesis ·Mark C. Kelley	13
4	Associations of Hormone-Related Factors With Breast Cancer Risk According to Hormone Receptor Status Among White and African American Women 2014 ·Clinical Breast Cancer ·Yong Cui, Sandra Deming-Halverson, Martha J. Shrubsole, Alicia Beeghly‐Fadiel, Alecia M. Fair, Maureen Sanderson, Xiao‐Ou Shu, Mark C. Kelley, Wei Zheng	26
5	APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry 2013 ·Carcinogenesis ·Xuan Dong, Guoyin Li, Qiuyin Cai, Sandra Deming-Halverson, Martha J. Shrubsole, Xiao‐Ou Shu, Mark C. Kelley, Wei Zheng, Jirong Long	82
6	Adjuvant Radiation Therapy Increases Disease-Free Survival in Stage IB Merkel Cell Carcinoma 2013 ·Annals of Plastic Surgery ·Kevin W. Sexton, (unknown), John B. Hill, Alexandra M. Schmidt, Ashit Patel, Gabriel A. Del Corral, Jason Axt, Mark C. Kelley, Wesley P. Thayer, (unknown)	16
7	Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials 2012 ·PLoS ONE ·Christine M. Lovly, Kimberly B. Dahlman, (unknown), Zengliu Su, Dora Dias‐Santagata, Donna J. Hicks, Donald Hucks, Elizabeth Berry, Charles R. Terry, (unknown), Yingjun Su, Tammy Sobolik-Delmaire, Ann Richmond, Mark C. Kelley, Cindy L. Vnencak‐Jones, A. John Iafrate, Jeffrey A. Sosman, William Pao	149
8	Protein signatures for survival and recurrence in metastatic melanoma 2011 ·Journal of Proteomics ·(unknown), Mark C. Kelley, Deming Mi, Robert L. Low, Richard M. Caprioli	98
9	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma 2011 ·Annals of Surgery ·Sojun Hoshimoto, Mark B. Faries, Donald L. Morton, Tatsushi Shingai, Christine Kuo, (unknown), Robert M. Elashoff, Nicola Mozzillo, Mark C. Kelley, John F. Thompson, Jeffrey E. Lee, Dave S.�B. Hoon	72
10	Foamy cell angiosarcoma: a rare and deceptively bland variant of cutaneous angiosarcoma 2010 ·Journal of Cutaneous Pathology ·(unknown), Vicki L. Keedy, Scott R. Florell, Jean F. Simpson, Cheryl M. Coffin, Mark C. Kelley, Justin Cates	16
11	An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites 2007 ·Journal of Clinical Oncology ·D L Morton, N Mozzillo, John F. Thompson, Mark C. Kelley, Mark B. Faries, Jeffrey D. Wagner, Schlomo Schneebaum, Lynn M. Schuchter, Guy Gammon, Robert M. Elashoff	126
12	Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer 2006 ·Clinical Cancer Research ·A. Bapsi Chakravarthy, Mark C. Kelley, Bernadette K. McLaren, Cristina I. Truica, Dean Billheimer, Ingrid A. Mayer, Ana M. Grau, David H. Johnson, Jean F. Simpson, R. Daniel Beauchamp, Catherine Jones, Jennifer A. Pietenpol	59
13	Sentinel lymph node detection and microstaging in vulvar carcinoma. 2001 ·PubMed ·Kelly L. Molpus, Mark C. Kelley, Joyce E. Johnson, William H. Martin, Howard W. Jones	31
14	Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients 1998 ·Seminars in Surgical Oncology ·David W. Ollila, Mark C. Kelley, Guy Gammon, Donald L. Morton	32
15	Ratio of IgG: IgM antibodies to sialyl LewisX and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice 1998 ·International Journal of Cancer ·Mepur H. Ravindranath, Mark C. Kelley, (unknown), (unknown), Philip M. Bauer, Donald L. Morton	24
16	Update on active specific immunotherapy with melanoma vaccines 1997 ·Journal of Surgical Oncology ·(unknown), David W. Ollila, Mark C. Kelley, Guy Gammon, Donald L. Morton	20
17	Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Lea, sialyl Lex, GD3 and GM2) better than soluble lysate cancer vaccine 1997 ·Anti-Cancer Drugs ·Mepur H. Ravindranath, Philip M. Bauer, (unknown), Seyed Mohammad Miri, Mark C. Kelley, (unknown), Donald L. Morton	11
18	Cost-conscious management of the inguinal nodes in early-stage melanoma 1997 ·Melanoma Research ·Richard Essner, (unknown), Mark C. Kelley, Leslie A. Wanek, D L Morton	3
19	Vasoactive Intestinal Peptide and Substance P Receptor Antagonists Improve Postoperative Ileus 1995 ·Journal of Surgical Research ·N. Joseph Espat, (unknown), Mark C. Kelley, (unknown), Charles A. Sninsky, Michael P. Hocking	52
20	Ketorolac prevents postoperative small intestinal ileus in rats 1993 ·The American Journal of Surgery ·Mark C. Kelley, Michael P. Hocking, (unknown), Charles A. Sninsky	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact